There is an error in the title of the original article. The correct title is “Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
multiple myeloma, maintenance, proteasome inhibitors, immunomodulators, optimal maintenance duration
Citation
Han X, Jin C, Zheng G, He D, Zhao Y, Li Y, Wu W, Zheng W, Wei G, Zhang E, Huang H, He J and Cai Z (2021) Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China. Front. Oncol. 11:740715. doi: 10.3389/fonc.2021.740715
Received
13 July 2021
Accepted
14 July 2021
Published
02 September 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
11 - 2021
Updates
Copyright
© 2021 Han, Jin, Zheng, He, Zhao, Li, Wu, Zheng, Wei, Zhang, Huang, He and Cai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jingsong He, hejingsong@zju.edu.cn; Zhen Cai, caiz@zju.edu.cn
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share the last authorship
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.